# of Displayed Technologies: 30 / 139


Targeting GSK3β in NK Cells for Enhanced Antitumor Activity.
TS-002302 — Acute myeloid leukemia (AML) causes myeloid cells to interfere with the production of healthy white blood cells, red blood cells and platelets; patients will experience fatigue, easy bruising, infections, etc. Due to expansion ex vivo with IL-15, AML patients and donors’ natural killer (NK) cells have an increase in glycogen synthase kinase 3 beta (GSK3β) from the loss of cytotoxicity and defective metabolism. Researchers at Nationwide Children’s Hospital targeted GSK3β in NK cells to promote antitumor activity by expanding NK cells with feeder cells expressing membrane-bound IL-21 without altering the GSK3β levels. They deleted GSK3β using the cas9/RNP and expanding paired-donor knock out and wild-type NK cells. When assessing transcriptional and functional alterations induced by the loss of GSK3β, GSK3β-KO cells demonstrated changes in gene expressions that suggested possible metabolic reprogramming and exhibited 150% higher spare respiratory capacity, a marker for metabolic fitness. By using mbIL21 expansion in the expansion of NK cells and GSK3β in these cells, the upregulation of GSK and drug inhibitors is prevented.
  • College:
  • Inventors: Lee, Dean; Naeimi Kararoudi, Meisam; Pereira, Marcelo
  • Licensing Officer: Corris, Andrew

Use of CD38 as the Integration Site for Enhanced Function of Gene-Modified Immune Effector Cells
TS-002301 — CD38 regulates the metabolism and the immunomodulation of tumor microenvironments, making it an essential component to anti-cancer therapies. Researchers at Nationwide Children’s Hospital developed a novel technology using CD38 as a new insertion site for NK and T cells. They generated CAR-NK and CAR-T cells by integrating the DNA encoding CAR in the CD38 locus to enhance anti-tumor activity and improve metabolic function of NK and T cells. Additionally, this can be used in combination with CD38 monoclonal antibodies without risking fratricide.
  • College:
  • Inventors: Lee, Dean; Naeimi Kararoudi, Meisam
  • Licensing Officer: Corris, Andrew

Chimeric Antigen Receptor Targeting CD38
TS-002300 — Hematologic cancers like leukemia, lymphoma and myeloma are found in 10% of adult cancer cases and 25% in pediatric cancer cases. Researchers at Nationwide Children’s Hospital’s Center for Childhood Cancer have developed a novel single-chain variable fragment (scFv) that targets and binds to CD38. The scFv can generate CD38 binding proteins, including chimeric antigen receptors (CAR), single-chain antibodies, multi-specific engagers, etc. Additionally, the single-chain variable fragments can be incorporated into polyfunctional proteins and have identical binding properties as CD38 antibodies which are used as anti-cancer therapeutics.
  • College:
  • Inventors: Lee, Dean; Naeimi Kararoudi, Meisam; Troy, Ella
  • Licensing Officer: Corris, Andrew

Manipulating Mammalian Gene Expression with Bacterial Extracellular Vesicles
TS-002167 — Research links increased expression of neuregulin-1 (NRG1) to neurological disorders (schizophrenia, bipolar disorder, autism spectrum disorder, epilepsy, etc.), cancers (breast, prostate, lung, gastric cancers), metabolic syndrome and multiple sclerosis. Researchers at Nationwide Children’s Hospital developed a treatment to manipulate mammalian gene expression with bacterial extracellular vesicles. This treatment based on outer membrane vesicle (OMV) modulates expression of NRG1 by using porphyromonas gingivalis (Pg) tRNA and NRG1 mRNA to reduce NRG1 translation. Pg and closely related pathogens produce OMVs that contain proteins, lipids, nucleic acids and cytosolic compounds. Through metagenomic sequencing, researchers found that Pg OMVs contain tRNA that complements mammalian NRG1 mRNA. They also found that the tRNA can potentially stop the translation of NRG1. This complementation indicates a direct interaction between Pg tRNA and NRG1 mRNA which results in the reduction of NRG1.
  • College: Technology Development Fund - TDF
  • Inventors: Lauber, Christian; Blalock, Lexie; Mashburn-Warren, Lauren
  • Licensing Officer: Corris, Andrew

Caring Contact Service Automation and Management
TS-002166 — Education and awareness about mental health increased the demand for better digital programs so health care professionals can reach patients outside the clinical setting. Researchers at Nationwide Children’s Hospital created a program that sends multimedia text messages to encourage positive thinking and to reduce chances of readmission to behavioral health hospitals.
Before the Caring Contact Service Automation and Management, clinical coordinators needed to manually send text messages to patients and to track their enrollment in the program. With this program, patients will be enrolled into the program and will receive the confirmative messages with configured …
  • College:
  • Inventors: Ackerman, John; Huang, Yungui; Oiler, Brannon; Thomas, Glenn
  • Licensing Officer: Corris, Andrew

Hair Care Equity Project
TS-002165 — Children have higher self-esteem when their needs are supported, which includes hair care. In 2020, staff members reported their knowledge gaps and lack of confidence and supplies regarding patient hair care. As a result, the Hair Care Equity Project was created at Nationwide Children’s Hospital to combat these challenges and to create a more inclusive environment for patients through education and product research. The Hair Care Equity Committee worked with vendors and dermatologists to carefully select products for trials and final selection. Now, staff members can access and order supplies for patients with all hair types.
Their educational tool includes interactive learning modules, instructional videos and charts detailing styling and hair tools. The modules provide in-depth procedure steps for detangling, washing, conditioning, moistrizing and styling keeping cultural considerations, accessories, oxygen safety, etc…
  • College:
  • Inventors: Asamoa, Surlina; Clark, Nimrah; Hoy, Jimia; Justice, Lauren; Miller, Robbii; Regis, Kimberly
  • Licensing Officer: Corris, Andrew

A Tailored mHealth Vaping Prevention Intervention for Adolescents with Congenital Heart Defects
TS-002164 — Congenital heart defects (CHD) are the most common birth defects with an occurrence rate of 1 in every 110 births. When transferring from pediatric to adult care, one-third of adolescents are in optimal cardiovascular health. Due to this, health behavior intervention is ideal in adolescence. This is especially crucial when youths report using e-cigarettes or the possibility of using one in the future. Researcher, Kristen Fox, at Nationwide Children’s Hospital created a tailored mHealth Vaping Prevention program for adolescents with CHD to reduce engagement with health risk behaviors. The curriculum is improved with added topics surrounding stress management and disease knowledge with the implementation of gamification and animations to facilitate knowledge and sustain engagement about tobacco product education.
By utilizing the mHealth format, the curriculum will reach and engage adolescents with content that classroom-based programs cannot or failed to in the past. For example, the curriculum includes a module about stress management that will cover goal setting, sleep hygiene, problem solving/ coping and…
  • College:
  • Inventors: Fox, Kristen
  • Licensing Officer: Corris, Andrew

Pediatric and Rare Disease Clinical Research: Your Reference Manual for Navigating a Complex Research Environment
TS-002163 — Researchers and professionals beginning their careers in pediatrics and/or rare disease clinical research sites may feel overwhelmed in the face of innovation, new territories and lifechanging research. A team of Certified Clinical Research Professionals at Nationwide Children’s Hospital created three additional modules for the Clinical Research Onboarding Program – The Survival Guide and an opportunity to access a Gene Therapy Immersion Program. Through this reference manual, the team hopes to share lessons and provide guidance on working in pediatrics clinical research for all learners.
The three modules focus on pediatrics and rare disease clinical research: Pediatric Clinical Research, Pediatric Rare Disease Clinical Research and Study Management for Pediatric and Rare Disease Clinical Research. Like the previous six modules, the new modules are also in-depth and combat challenge…
  • College:
  • Inventors: Wentzel, Grace; Baker, Christine; Roush, Kandice
  • Licensing Officer: Corris, Andrew

Gastric Secretion Reinfuser (GSR)
TS-002162 — Dr. Jonathon Gisser, a pediatric gastroenterologist at Nationwide Children’s Hospital, researched and created a process called Gastric Secretion Reinfusion (GSR) to help salvage gastric fluids by reinfusing them into the jejunum. Gastrojejunostomy (GJ) tubes cause increased vomiting and/or gastric drainage in patients due to gastric outlet obstruction. The small intestine needs gastric fluids to prevent dehydration, dysmotility, malabsorption, malnutrition, electrolyte imbalances and increased gastric output because they are rich in electrolytes, enzymes and hormones. Currently, gastric fluids are typically discarded and replaced by nutrient-impoverished, exogenous fluids like intravenous fluids (IV). By implementing the Gastric Secretion Reinfusion technique, patients will experience decreased incidences of electrolyte abnormalities, vomiting and reliance on parenteral access and Total Parenteral Nutrition (TPN). Additionally, they will also experience an increase in tolerance of jejunal feeds and improved nutrition.
  • College:
  • Inventors: Gisser, Jonathan
  • Licensing Officer: Corris, Andrew

Staffing Analysis Tool
TS-002161 — The Staffing Analysis Tool helps organizations track and plan for staffing in the future. Inventors at Nationwide Children’s Hospital developed this smart spreadsheet for workplaces to effectively see staffing levels easily and automatically through its real time updates. Users only need to input staffing needs and staff information into its built-in functions. Once completed, the Staffing Analysis Tool will comprise the information to create an overall picture of staffing insufficiencies including planned leaves, resignations and other challenges. With the final picture calculated, workplaces can always ensure effective staffing.
  • College:
  • Inventors: Larouere, Marissa; Michael, Jeanine
  • Licensing Officer: Corris, Andrew

IDDSI Implementation Manual and Education
TS-002160 — Dysphagia affects 300,000 to 700,000 Americans every year. Individuals of any age can suffer with dysphagia which increases the demand for education and information. Providers working with individuals with dysphagia require easy, quick access to education and information regarding implementing the International Dysphagia Diet Standardization Initiative (IDDSI). Clinicians at Nationwide Children’s Hospital created the IDDSI Implementation Manual and Education. The manual provides healthcare providers with specific implementation steps, instructions and details to guide teams to successfully integrate IDDSI in their healthcare organization quickly along with additional supplemental educational materials.
  • College:
  • Inventors: O'Rourke, Sara; Coleman Casto, Shelley; Patton, Rebecca; Stevens, Melanie
  • Licensing Officer: Corris, Andrew

Therapeutic Recreation (TR) Leisure Engagement
TS-002159 — Currently, there is no standard protocol for observing patient readiness for recreational therapy. Inventors at Nationwide Children’s Hospital created the Therapeutic Recreation (TR) Leisure Engagement tool to document and assess the needs of patients with developmental or physical disabilities to promote well-being and recovery. Through this technology, therapeutic recreation specialists will further help patients by measuring their readiness for sessions, emotional presentation and social functions while providing leisure education.
  • College:
  • Inventors: Lazzara Mould, Valerie; Chadbourne, Mary; Sotak, Heather
  • Licensing Officer: Corris, Andrew

GEMys: Therapeutic Effect of Genetically Engineered Bone Marrow Derived Myeloid Cells in Central Nervous System Tumors
TS-001983 — A research team at Nationwide Children’s Hospital developed a new therapeutic approach for treating low-grade gliomas and other immune suppressive premetastatic solid tumors in adolescents and young adults. The innovative approach uses autologous bone marrow isolated myeloid cells (GEMys) to encourage stable expression and secretion of interleukin 2 (IL2), a cytokine responsible for responding to invading pathogens and the recruitment of cytotoxic anti-cancer immune cells at the tumor microenvironment (TME). The bone marrow derived GEMys can express and release other cytokines like cytotoxic T and NK cells to kill tumor cells and prevent glioma progression. The therapeutic is performed through intravenous injection which avoids immune depletion caused by chemotherapy.
  • College:
  • Inventors: Rajappa, Prajwal; Canella, Alessandro
  • Licensing Officer: Corris, Andrew

AAV Vectors Containing U7small Nuclear RNA (U7snRNA That Interferes With The CTGexp or Silences DMPK)
TS-001229 — Mutations in the Myotonic Dystrophy Protein Kinase gene (DMPK) cause an autosomal dominant inherited disease referred to as Myotonic Dystrophy. Myotonic Dystrophy affects more than 1 in 8,000 people worldwide. Myotonic dystrophy results in progressive muscle weakness, stiffness and wasting. Currently, here are no treatments for this disease. A team of researchers at Nationwide Children’s Hospital have designed short hairpin constructs of AAV-shRNA which can be used to silence DMPK mRNA and therefore potentially treat myotonic dystrophy.
  • College:
  • Inventors: Wein, Nicolas
  • Licensing Officer: Eidahl, Jocelyn

Second Generation Closed Seeding System for the Tissue Engineered Vascular Graft
TS-001227 — A team of physicians at Nationwide Children's Hospital have developed a process to improve the acceptance of implanted vascular grafts. This Tissue Engineered Vascular Graft (TEVG) is patient-specific. It seeds patient cells onto a biodegradable tubilar scaffold, which is designed to dissolve with hydrolysis so that only the growing vessel remains. This system, the Closed Seeding System, combines patient imaging data, 3D-printing capabilities, and efficient collection and subsequent seeding of patient cells onto the TEVG scaffolding.
  • College:
  • Inventors: Breuer, Christopher; Hibino, Narutoshi
  • Licensing Officer: Murrah, Kyle

Sweat Technology for Monitoring Cystic Fibrosis Health and Adherence
TS-001225 — Cystic fibrosis is an inherited disorder that affects cells that produce sweat and mucus, causing significant damage to the digestive system, lungs, and other organs. A team at Nationwide Children's Hospital has developed a non-invasive monitoring system to track and test a patient with this disease. This technology is a skin patch that measures the metabolomics of the patients sweat to evaluate the clinical health of patients afflicted with cystic fibrosis.
  • College:
  • Inventors: Hayes, Don; Kopp, Benjamin; Woodley, Frederick
  • Licensing Officer: Murrah, Kyle

Preference Cards and Decision Aid to Facilitate Shared Decision Making in Contraceptive Counseling
TS-001224 — Decks of cards have been used to facilitate knowledge for decades. A team of researchers led by Dr. Elise Berlan have developed a series of cards that combine summaries of contraceptive counciling information and patient preferences. This includes key components of contraceptive preferences which can then be used with a care provider to determine the best form of contraceptive for the patient's preference and decreases the stigma associated with discussing topics like contraceptives as adolecents or young adults.
  • College:
  • Inventors: Berlan, Elise
  • Licensing Officer: Murrah, Kyle

Machine Learning of Doppler Echocardiographic Coronary Blood Flow
TS-001178 — Currently there are few existing methods on coronary flow pattern automation. The DECFA platform fulfills this unmet need by predicting diseased coronary blood flow by integrating previously unutilized data features from (sonographic) Doppler echocardiography measurements, cardiac functional and other physiological data (e.g. heart rate, body weight, etc) using machine learning. The DECFA program is superior to manual intervention as it provides more efficient analysis, more accurately, and can accept raw video files of PW Doppler and Color Doppler B-mode files, applicable on mouse models, potentially applicable to humans. DECFA can analyze raw PW Doppler AND Color Doppler B-Mode AVI video files to calculate overall coronary blood flow and coronary flow reserve, and the separation of each coronary flow pattern into 4 distinct phases representative of the stages in a cardiac cycle. Benefits: More efficient analysis over manual intervention, less error than manual intervention, capable of accepting raw video files of PW Doppler and Color Doppler B-mode files, applicable on mouse models, potentially applicable to humans (not yet validated). New features include the analysis of raw PW Doppler AND Color Doppler B-Mode AVI video files to calculate overall coronary blood flow and coronary flow reserve, and the separation of each coronary flow pattern into distinct phases representative of the stages in a cardiac cycle. The machine learning aspect brings state-of-the-art technology to determine whether it may be useful in directly predicting/diagnosing coronary microvascular disease. Stage of Development: We are currently in the final stages of completing the data analysis for all of the in vivo coronary and cardiac physiological parameters that will be used to perform the final runs through the machine learning process. We did perform an “interim” analysis using about half of the data, the results of which were promising (inconclusive at this point, but they put the predictive value of coronary flow patterns above 90% for identifying diseased coronary blood flow). This process also uses the whole envelope instead of discrete points of the coronary flow pattern, in addition to the texture-analysis extension. After this process is complete in mice, we plan to obtain human coronary blood flow patterns to determine whether this could be clinically useful beyond research applications. Potential Applications/Markets: Our program could be utilized in a research setting for robust, comprehensive, and more efficient analysis of coronary flow patterns in mice measured through Doppler Echocardiography (It solves the problem of large inter/intra observer error and time required for manual analysis). The program could also be used clinically for use in the medical field for the same analysis if adjusted for human use. It could also be used as an add on feature to the VisualSonics Vevo 2100 software for added capabilities in analyzing PW Doppler coronary flow patterns and Color Doppler B-mode files. The parameters that we identify in our program could be potentially useful in clinical diagnostics/machine learning/prediction modeling for better identifying and predicting disease. Furthermore, we envision that this could be tested and applied to clinical coronary Doppler echocardiograms, with the readout being predictability of coronary microvascular disease based on the machine learning algorithm of coronary flow patterns. Opportunity/Seeking: Development Partner Commercial Partner Licensing IP Status: Know-how based Copyright
  • College:
  • Inventors: Trask, Aaron; Bartlett, Christopher; Bossenbroek, Jamie; McCallinhart, Patricia; McDermott, Michael; Ray, William; Sunyecz, Ian; Ueyama, Yukie
  • Licensing Officer: Corris, Andrew

Child-Restraint Spray-Bottle for Household Cleaning Products
TS-001037 — When it comes to the safety of our children, innovation never stops. There have been many improvements to the safety of devices and receptacles that can be toxic or life threatening if consumed or exposed to skin. A team of researchers at Nationwide Children’s Hospital have incorporated this desire for security into a common household product: the spray bottle. Often filled with harmful chemicals, spray bottles remain one of the leading causes of chemical exposure injuries in children. The team at NCH has developed a “two-step authentication” spray nozzle that requires the dexterity beyond that of a small child. This dual trigger approach requires a full grip that prevents kids from accessing the contents of the spray bottle, while remaining easily usable by adults and seniors.
Benefits and Applications: Inventors anticipate that incorporating this product into households will result in a decline in child injury due to accidental activation of spray bottles. Stage of Development:
  • College: Technology Development Fund - TDF
  • Inventors: McKenzie, Lara; Nelson, Nicolas; Roberts, Kristin
  • Licensing Officer: Murrah, Kyle

A Virtual Reality Simulation to Aid in Exposure to Therapy for School Avoidance
TS-001036 — School can be a daunting experience. Constant motion, public speaking and a new environment can increase anxiety in children, sometimes leading to school avoidance. A team at Nationwide Children’s Hospital has developed a solution, where exposure therapy procedures are combined with modern technology can improve the school experience for people of all ages. Using a Virtual Reality (VR) Simulation, clinicians are able to use the multi-user capability to interact with and guide their patient through new environments such as classrooms, hallways and lunchrooms, as well as scenarios known to trigger increased anxiety such as public speaking or asking for help. Biofeedback components help collect data so that the clinician can adapt the experience to the user. Although targeted for school-aged children, this technology can be modified to treat any person with school or public phobia.
  • College:
  • Inventors: Huang, Yungui; DeForte, Shelly; Luna, Juan (John) "John"; Mackner, Laura ; Vickery, Elizabeth
  • Licensing Officer: Murrah, Kyle

RyaBhata: A Shiny R Application for Single Cell Transcriptome Data Analysis and Visualization
TS-001035 — Shiny R is an open source platform that allows a framework to develop online applications. With minimal required background in coding principles, a team of researchers at Nationwide Children’s Hospital were able to display and interact with the analysis made of single-cell transcriptome. Shiny R generates visualizations that include UMAP plots and presents features of single-cell RNA and transcriptomic data without extensive training in R programming. Improvements made on this existing technology includes importing data, cell filtration, principle component analysis, clustering, dimensional reduction, merging datasets, and Graphical user interface (GUI)-based generations of gene expression plots. This significantly improves the visualization and analysis of single-cell transcriptome analysis.
  • College:
  • Inventors: Manivannan, Sathiyanarayanan ; Garg, Vidu
  • Licensing Officer: Murrah, Kyle

Small Molecules that Inhibit and Disperse Salmonella Biofilms in vitro and are Active in Combination with Ciprofloxacin in vivo
TS-001034 — Salmonella is often caused by contact with animals that carry bacteria, contaminated food, or water. It has been observed that children are commonly afflicted by salmonella, and typically treatment includes fluids, medical care, and sometimes pharmaceuticals. A team of researchers at Nationwide Children’s hospital have identified a lead compound that includes a biofilm with anti-salmonella characteristics and acts as an inhibitor. Use of this compound with the antibiotic ciprofloxacin improves the elimination of bacterial infection in at-risk organs such as the liver and spleen.
  • College:
  • Inventors: Gunn, John; Sandala, Jenna
  • Licensing Officer: Murrah, Kyle

Automated Processing of Venous Intravascular Ultrasound Image
TS-001033 — Intravascular Ultrasound Images (IVUS) is a process that uses micro technology to provide images of blood vessels, their inner walls (endothelium) and the inside of veins. The analysis of these images allows clinicians to analyze luminal and scaffold boundaries, identify the presence of stenosis, and perform computations of various geometric quantities. This process is fully automated and therefore eliminates inconsistencies and inefficiencies that are a direct result of current semi-automated or complex fully automated systems already in place.
  • College:
  • Inventors: Ulziibayar, Anudari
  • Licensing Officer: Murrah, Kyle

Use of Tamoxifen to Reduce Breast Implant Capsule Formation and Capsular Contracture
TS-001029 — A major complication associated with breast implant prostheses is the occurrence of capsular contracture, occurring in 20%-25% of patients. Severe forms of capsular contracture constitute failure of the reconstruction with significant implications for increased cost owing to an increased need for recurrent medical interventions, as well diminished quality of life for patients. Capsular contracture occurs as the result of the patient’s immunologic ‘foreign body’ response to the implant material. The inventors’ vision is to develop a technology whereby the active metabolites of Tamoxifen (endoxifen) are conjugated to implant biomaterial in a manner allowing for localized delivery of endoxifen. They anticipate that local delivery of endoxifen will successfully reduce capsule formation around implant material by reducing the immunologic foreign body response. This is a technology that could be licensed to implant manufacturers (breast, implantable cardiac devices, etc.) Technology Overview: Breast augmentation and reconstruction is a common practice, especially in those afflicted by breast cancer. One of the most common issues that comes with this process is the formation of capsular contracture. This is a direct result of the patient’s immunologic ‘foreign body’ response to the implant material, which can impact the need for significant medical interventions and diminished quality of life. The current pharmacologic treatment for breast cancer is the chemical compound known as Tamoxifen, which acts as a chemo-preventative medication for hormone sensitive breast cancers. A team of researchers at Nationwide Children’s Hospital and Ohio State University aims to localize the delivery of tamoxifen to significantly reduce the immunologic foreign body response around implant material for use in both cancer-based breast reconstruction and cosmetic procedures Benefits: No pharmacotherapeutics currently exist to address capsular contracture and no biomaterial advances have been made to specifically reduce the foreign body response to breast implants Stage of Development: Mouse studies are currently underway using systemic delivery of Tamoxifen for treatment of capsular contracture in breast implants. A manuscript is in preparation. Future mouse studies will focus on local delivery of endoxifen for treatment of capsular contracture in breast implants; then look at other implant types and different coating types. Potential Applications / Markets: According to the report published by Allied Market Research, the medical implant industry estimated $85.38 billion in 2019, and is estimated to generate $147.46 billion by 2027, manifesting a CAGR of 7.2% from 2020 to 2027. According to a report published by Fortune Business Insights, the breast implant market was worth $2.76 billion in 2019 and is projected to reach $3.05 billion by the end of 2027, exhibiting a CAGR of 7.2% during the forecast period, 2020-2027. Opportunity / Seeking: -Licensing IP Status: Patent application submitted
  • College:
  • Inventors: Blum, Kevin
  • Licensing Officer: Murrah, Kyle

Overcoming Immune Checkpoint Inhibition with VISTA Deficient NK Cells – ViDe* NK Cells
TS-000972 — Natural Killer (NK) cells express a range of receptors to activate or inhibit certain cellular behavior to kill cancer cells. When an NK cell is deficient or dysfunctional, the efficiency of the NK cells is severely limited. VISTA is a protein sequence that activates T cells and acts as a moderator for the immune system. It has low-to-moderate expression but has been the target of study by a team of researchers at Nationwide Children’s Hospital led by Dr. Dean Lee. By removing VISTA in expanded NK cells, the inhibitory signal will be eliminated and thus resulting in an enhanced ability of NK cells to target cancers and overcome the immune-suppressive signals for improved cancer immunotherapy.
  • College:
  • Inventors: Lee, Dean; Pereira, Marcelo
  • Licensing Officer: Corris, Andrew

Live Attenuated Mumps Virus-Based SARS-CoV-2 Vaccines for Infants and Children
TS-000971 — The novel disease Coronavirus, also denoted as COVID-19, was recognized by the World Health Organization as an unknown etiology in December of 2019. Severe Acute Respiratory Syndrome (SARS) is a disease that presents flu-like symptoms that is caused by coronavirus (SARS-CoV). The current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing tremendous economical, emotional, and public health burdens. A team of researchers at Nationwide Children’s Hospital have reengineered a live attenuated recombinant mumps virus to create a novel SARS-CoV-2 vaccine for infants and children under the age of twelve. As vaccination is the most effective strategy to prevent infectious diseases, this development is instrumental to the outcome of the COVID-19 pandemic.
  • College:
  • Inventors: Peeples, Mark; KC, Mahesh
  • Licensing Officer: Zalucha, Ellen

Generation of Antigen-Specific Chimeric Antigen Receptor T cells Using Cas9/RNP and AAV
TS-000969 — Gene therapy experts at Nationwide Children’s Hospital have made significant advancements in designing optimal viral vectors for producing Good Manufacturing Practice (GMP)-grade viral vector products. Adeno-associated virus (AAV) serotypes such as AAV1, 2, 2.5, 3, 5, 6, 8, 9 and rh74 have properties optimized by these researchers. Chimeric Antigen Receptor T cells (CAR T) are comprised of an extracellular antigen recognition domain, intracellular T cell activation and co-stimulatory domains. These cells allow for potent and specific targeting of cancer cells, bypassing the need for antigen presentation and T cell receptor recognition. Generating CAR T cells using the process of lentiviral transduction has limitations stemming from the random integration of transgenesis, where oncogene activation, gene silencing, or negative effects on the CAR T antitumor efficacy are possible.
  • College:
  • Inventors: Lee, Dean; Naeimi Kararoudi, Meisam
  • Licensing Officer: Corris, Andrew

Priming Peptide Pools for Isolation of SARS-CoV-2-Specific T Cells
TS-000913 — Peptides can be used to stimulate antigen-specific T cells, allowing activated T cells to be isolated from immune individuals to be used in vaccination or treatment in others. The novel disease Coronavirus, also denoted as 2019-nCoV, was recognized by the World Health Organization as an unknown etiology in December of 2019. Severe Acute Respiratory Syndrome (SARS) is a disease that presents flu-like symptoms that is caused by coronavirus (SARS-CoV). A current process widely applicable to many pathogens uses the Miltenyi Prodigy device. In a study led by Dr. Dean Lee, his team found that this process can be adapted to SARS-CoV-2 using a specialty mix of peptides to isolate T cell immunity.
  • College:
  • Inventors: Lee, Dean
  • Licensing Officer: Corris, Andrew

A Novel Compound, GQ-16 Protects Against Kidney Disease with Additional Insulin Sensitizing Benefits and Reduced Side Effects
TS-000912 — There are a few prominent diseases that affect the kidney, such as nephrotic syndrome and diabetic nephropathy. To treat Type II diabetes, there is a readily available pharmaceutical known as pioglitazone that is often used in conjuncture with other compounds to reduce proteinuria in patients with kidney diseases. A team of researchers at Nationwide Children’s Hospital have developed a novel compound to act as a treatment agent in cases of kidney disease. The new design has similar insulin sensitizing effects as pioglitazone as well as its ability to reduce proteinuria. This compound, titled GQ-16, has similar efficacy as traditional Type II diabetes drugs and acts as a new indication for nephrotic syndrome or kidney diseases, with a significant reduction in side effects such as weight gain or adipogenesis.
  • College:
  • Inventors: Agrawal, Shipra
  • Licensing Officer: Corris, Andrew

Dual Targeting CD38KO and CARKI NK Cell Immunotherapy
TS-000906 — Natural Killer (NK) cells express a range of receptors to activate or inhibit certain cellular behavior to kill cancer cells. Additionally, CD38 presenting cells have been used as a marker for cancer stem cells, specifically those that often avoid recognition when common surface antigen processes are used. CARK1 is a phosphorylate that impacts cell growth and development. A team led by Dr. Dean Lee has developed CD38k0 NK cells that they combine with CARK1 to create a series of monoclonal antibodies that targets cancer cells. Along with better cell targeting, this combination improves the efficacy of treatment in comparison to the CAR, NK, or CD38 antibodies as independent components.
  • College:
  • Inventors: Lee, Dean; Naeimi Kararoudi, Meisam
  • Licensing Officer: Corris, Andrew

Show More Technologies

Loading icon